Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 July 2021 | Story Leonie Bolleurs | Photo UFS Photo Archive
Prof Hendrik Swart played a key role in the Department of Physics acquiring the PHI Quantes XPS system, the first in Africa and one of only 20 in the world.

The state-of-the-art equipment in the Department of Physics at the University of the Free State (UFS) differentiates this department from its competitors. Availability of the equipment makes it possible for researchers as well as students to deliver work that receives national and international recognition. 

Recently, the department acquired a PHI Quantes XPS system, the first in Africa and one of only 20 in the world. 

Creating better phosphor 

“The Quantes XPS system uses X-rays to determine the chemical composition of molecules on the surface of a sample. The system is unique in the sense that it also has an extra X-ray source that can determine the chemical state below the surface, which was not possible in the past.  This will help us to dictate the position of defects in our phosphor materials that will consequently enable us to create better phosphor for solid state lighting as well as solar cell applications,” explains Prof Hendrik Swart, Senior Professor in the Department of Physics, who also holds the SARChI Chair in Solid State Luminescent and Advanced Materials.

After he had the opportunity to observe the system in the factory in Chigasaki, Kanagawa, Japan, where he attended a conference, Prof Swart was very impressed by its performance. He discussed it with Prof Koos Terblans, Head of the department, and other colleagues, and started making plans to buy the system. 

When the department first bought the X-ray photoelectron spectroscopy (XPS) system in 2007/2008, it became the national facility on XPS measurements. Not only is this an upgrade of the XPS system bought 14 years ago, but the new system will enable the department to do more measurements. “The number of samples that we have to handle has just become too much for one system. The new system’s increased capacity for making measurements addresses this challenge and it also gives UFS scientists and postgraduate students more time to spend on fundamental measurements to develop research of a higher level,” says Prof Swart.

(The Quantes XPS system. Photo:Supplied)

Explaining about the measurements, Prof Swart says: “This advanced X-ray photoelectron spectroscopy (XPS) instrument has the capability to analyse the very small area that the user is interested in and a large area of the uniform sample surface. The two different types of X-ray sources – the hard X-ray source and the more conventional soft X-ray source – can be switched automatically, allowing users to analyse the same area and/or points of a sample. The PHI Quantes XPS system ensures the availability of superior features such as automatic analysis, automatic sample transfer, turnkey charge neutralisation, and advanced data processing.”

“This XPS instrument is designed to pioneer new methods and applications transcending conventional ideas of what is possible.”

Optimising efficiency of materials

Prof Swart says the Department of Physics, especially the Research Chair in Advanced and Luminescent Materials, is developing new high-technology materials on a daily basis. “It is very important to know the chemical composition and defect distribution of the materials in order to add value to the fabrication of these materials,” he adds.

“The distribution of these defects is vital for the efficiency of the phosphor materials. If we know where these defects are located, we can determine the mechanisms of the light output coming from these phosphors,” describes Prof Swart.

Research conducted as part of the Research Chair in Solid State Luminescent and Advanced Materials will benefit significantly from this new system.

(Prof Koos Terblans, Head of the Department of Physics next to the Quantes XPS system. Photo:Supplied) 

“We are currently concentrating on phosphors as sensors (temperature), light-emitting diodes (LEDs), and solar cells, where we optimise the efficiency and durability of these materials. Any new knowledge, which I believe the PHI Quantes XPS system will provide us, will help us to reach our goal much quicker,” he says. 

Apart from the positive impact on research, the PHI Quantes XPS system will also be a benefit to society in the long term. Improved LEDs can be used to save electricity, and better solar cells can help to generate electricity, to mention but two examples. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept